

Michael Kreuter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3751262/publications.pdf>

Version: 2024-02-01

93
papers

6,281
citations

101384

36
h-index

74018

75
g-index

97
all docs

97
docs citations

97
times ranked

6537
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis. <i>Respiratory Research</i> , 2022, 23, 62.	1.4	7
2	Gender Differences in Health Care Workersâ€™ Risk-Benefit Trade-Offs for COVID-19 Vaccination. <i>Respiration</i> , 2022, 101, 646-653.	1.2	4
3	Editorial: Interstitial Lung Disease Around the World. <i>Frontiers in Medicine</i> , 2022, 9, 865334.	1.2	0
4	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. <i>Advances in Therapy</i> , 2022, 39, 1081-1095.	1.3	6
5	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, e18-e47.	2.5	780
6	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. <i>Annals of the American Thoracic Society</i> , 2022, 19, 833-844.	1.5	23
7	Prognostic Value of Oxygenated Hemoglobin Assessed during Acute Exacerbations of Chronic Pulmonary Disease. <i>Respiration</i> , 2021, 100, 387-394.	1.2	4
8	Profibrotic epithelial TGF- β 1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L356-L367.	1.3	12
9	The Diagnosis and Treatment of Pulmonary Fibrosis. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, .	0.6	10
10	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. <i>Respiratory Research</i> , 2021, 22, 109.	1.4	65
11	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 476-486.	5.2	254
12	Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review. <i>Annals of the American Thoracic Society</i> , 2021, , .	1.5	10
13	Global incidence and prevalence of idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2021, 22, 197.	1.4	170
14	One-step closer to solve the mystery of predicting disease progression in systemic sclerosis associated interstitial lung disease?. <i>Thorax</i> , 2021, 76, 1170-1171.	2.7	0
15	Cost drivers in the pharmacological treatment of interstitial lung disease. <i>Respiratory Research</i> , 2021, 22, 218.	1.4	5
16	Interstitial lung diseases: quo vadis?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1084-1087.	5.2	4
17	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2021, 100, 238-271.	1.2	19
18	Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2021, 57, 2003002.	3.1	37

#	ARTICLE	IF	CITATIONS
19	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. <i>European Respiratory Journal</i> , 2021, 57, 2004219.	3.1	2
20	Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. <i>Respiratory Research</i> , 2021, 22, 268.	1.4	24
21	Diagnostic Yield of Transbronchial Lung Cryobiopsy Compared to Transbronchial Forceps Biopsy in Patients with Sarcoidosis in a Prospective, Randomized, Multicentre Cross-Over Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 5686.	1.0	2
22	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 147-157.	5.2	410
23	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. <i>Respiratory Research</i> , 2020, 21, 12.	1.4	29
24	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e36-e69.	2.5	508
25	The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020, 21, 197.	1.4	33
26	Tobacco Use, Knowledge about Smoking-Associated Risks, and Cessation Programs among Dental Students in Germany – ToDent. <i>Respiration</i> , 2020, 99, 764-770.	1.2	1
27	Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment – a German claims data analysis. <i>Respiratory Research</i> , 2020, 21, 73.	1.4	10
28	Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression. <i>American Journal of Hematology</i> , 2020, 95, 1158-1169.	2.0	25
29	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSISA® trials. <i>Respiratory Research</i> , 2020, 21, 36.	1.4	29
30	<scp>SARS</scp> –CoVâ€2 receptor <scp>ACE</scp> 2 and <scp>TMPRSS</scp> 2 are primarily expressed in bronchial transient secretory cells. <i>EMBO Journal</i> , 2020, 39, e105114.	3.5	812
31	Evolution and treatment of idiopathic pulmonary fibrosis. <i>Presse Medicale</i> , 2020, 49, 104025.	0.8	15
32	A Comparison of Existing Questionnaires for Identifying the Causes of Interstitial and Rare Lung Diseases. <i>Respiration</i> , 2020, 99, 119-124.	1.2	8
33	Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease – a prospective, randomized, multicentre cross-over trial. <i>Respiratory Research</i> , 2019, 20, 140.	1.4	69
34	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1146-1153.	2.5	60
35	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. <i>Advances in Therapy</i> , 2019, 36, 3059-3070.	1.3	4
36	Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. <i>Respiratory Medicine</i> , 2019, 152, 25-31.	1.3	20

#	ARTICLE	IF	CITATIONS
37	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2019, 53, 1900539.	3.1	8
38	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). <i>BMJ Open Respiratory Research</i> , 2019, 6, e000422.	1.2	79
39	Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!. <i>European Respiratory Journal</i> , 2019, 53, 1900615.	3.1	2
40	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. <i>ERJ Open Research</i> , 2019, 5, 00215-2018.	1.1	5
41	Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease. <i>Respiration</i> , 2019, 97, 348-354.	1.2	37
42	The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. <i>European Respiratory Journal</i> , 2019, 53, 1801587.	3.1	50
43	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. <i>Respiration</i> , 2019, 97, 173-184.	1.2	39
44	Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2018, 95, 301-309.	1.2	66
45	Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. <i>Leukemia</i> , 2018, 32, 1762-1767.	3.3	27
46	Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases – a claims data analysis. <i>Respiratory Research</i> , 2018, 19, 73.	1.4	47
47	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 356-363.	2.5	193
48	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1036-1044.	2.5	174
49	Patients with IPF and lung cancer: diagnosis and management. <i>Lancet Respiratory Medicine</i> , 2018, 6, 86-88.	5.2	67
50	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , 2018, 27, 180078.	3.0	20
51	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000289.	1.2	48
52	Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies. <i>Respiration</i> , 2018, 96, 571-587.	1.2	21
53	Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2018, 52, 1800564.	3.1	54
54	C-proSP-B: A Possible Biomarker for Pulmonary Diseases?. <i>Respiration</i> , 2018, 96, 117-126.	1.2	15

#	ARTICLE	IF	CITATIONS
55	Gazing into the crystal ball: can treatment response be predicted in IPF?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 570-572.	5.2	2
56	Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. <i>Respiratory Research</i> , 2018, 19, 101.	1.4	36
57	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2018, 96, 314-322.	1.2	41
58	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. <i>Respiration</i> , 2018, 96, 514-524.	1.2	54
59	The yin and yang of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1602316.	3.1	4
60	What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. <i>ERJ Open Research</i> , 2017, 3, 00065-2016.	1.1	31
61	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. <i>Thorax</i> , 2017, 72, 148-153.	2.7	66
62	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. <i>Respiration</i> , 2017, 93, 415-423.	1.2	63
63	Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 418-425.	1.2	17
64	A Novel Lipid Biomarker Panel for the Detection of Heart Failure with Reduced Ejection Fraction. <i>Clinical Chemistry</i> , 2017, 63, 267-277.	1.5	19
65	The threat in chronic lung diseases: acute exacerbations. <i>European Respiratory Review</i> , 2017, 26, 170075.	3.0	12
66	Palliative care in interstitial lung disease: living well. <i>Lancet Respiratory Medicine</i> , 2017, 5, 968-980.	5.2	185
67	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. <i>European Respiratory Journal</i> , 2017, 50, 1700936.	3.1	75
68	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 591-598.	5.2	71
69	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. <i>BMC Pulmonary Medicine</i> , 2017, 17, 122.	0.8	94
70	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. <i>Respiratory Research</i> , 2017, 18, 139.	1.4	135
71	Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. <i>PLoS ONE</i> , 2016, 11, e0151425.	1.1	223
72	Photoaging smartphone app promoting poster campaign to reduce smoking prevalence in secondary schools: the Smokerface Randomized Trial: design and baseline characteristics. <i>BMJ Open</i> , 2016, 6, e014288.	0.8	34

#	ARTICLE	IF	CITATIONS
73	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. <i>European Respiratory Journal</i> , 2016, 48, 1524-1526.	3.1	16
74	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. <i>Lancet Respiratory Medicine</i> , 2016, 4, 381-389.	5.2	189
75	Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 445-453.	5.2	108
76	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016, 47, 1776-1784.	3.1	61
77	Interstitial lung diseases: course report. <i>Breathe</i> , 2016, 12, 213-215.	0.6	1
78	Pleuroparenchymal fibroelastosis in association with carcinomas. <i>Respirology</i> , 2016, 21, 191-194.	1.3	13
79	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2016, 4, e48.	5.2	6
80	Screening for <i>Helicobacter pylori</i> in Idiopathic Pulmonary Fibrosis Lung Biopsies. <i>Respiration</i> , 2016, 91, 3-8.	1.2	20
81	Optical coherence tomography detects structural abnormalities of the nasal mucosa in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 216-222.	0.3	19
82	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. <i>Pulmonary Therapy</i> , 2015, 1, 1-18.	1.1	2
83	Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). <i>PLoS ONE</i> , 2015, 10, e0130653.	1.1	40
84	Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry – The EXCITING-ILD Registry. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	42
85	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	60
86	IPF, comorbidities and management implications: Patient case 1. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2015, 32 Suppl 1, 24-5.	0.2	0
87	Management of idiopathic pulmonary fibrosis: selected case reports. <i>European Respiratory Review</i> , 2014, 23, 239-248.	3.0	4
88	Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry: Table 1. <i>BMJ Open Respiratory Research</i> , 2014, 1, e000010.	1.2	22
89	Emergency Ultrasound of the Chest. <i>Respiration</i> , 2014, 87, 89-97.	1.2	37
90	Impact and Safety of Adjuvant Chemotherapy on Pulmonary Function in Early Stage Non-Small Cell Lung Cancer. <i>Respiration</i> , 2014, 87, 204-210.	1.2	6

#	ARTICLE	IF	CITATIONS
91	Pirfenidone: an update on clinical trial data and insights from everyday practice. <i>European Respiratory Review</i> , 2014, 23, 111-117.	3.0	34
92	Supportive and Palliative Care of Advanced Nonmalignant Lung Disease. <i>Respiration</i> , 2011, 82, 307-316.	1.2	11
93	A 65-year-old man with an endobronchial gossypiboma after lobectomy for abscessing pneumonia. <i>Respiratory Care</i> , 2010, 55, 933-6.	0.8	2